Yaotang Bio develops gene editing therapies by combining LNP (Lipid Nanoparticle) delivery systems with advanced gene editing technology. This approach aims to precisely deliver genetic material to target cells for therapeutic applications.
Funding
Funding not disclosed
Founders
Product
Problem
Current gene editing therapies face challenges in efficiently and safely delivering genetic material to specific target cells within the body, limiting their therapeutic potential. Existing delivery methods often suffer from low delivery rates and off-target effects, hindering the development of effective gene editing treatments for various diseases.
Solution
YolTech is developing gene editing therapies that combine advanced gene editing technology with proprietary lipid nanoparticle (LNP) delivery systems to overcome these limitations. The company's AI-powered discovery platform leverages metagenomics data to identify novel genome editing tools, including YTDE and YolBE. YolTech's LNP delivery platform utilizes a library of novel ionizable cationic lipids and a high-throughput screening process to optimize delivery efficiency and safety. This approach enables precise and efficient delivery of gene editing payloads to target organs, including traditionally difficult-to-reach non-liver organs, for the treatment of genetic diseases. YolTech also has established a GMP production platform to support in-house large-scale LNP-mRNA and in vivo gene editing drug manufacturing.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing gene editing therapies for inherited diseases, as well as patients with genetic disorders seeking advanced treatment options.
Features
- Novel Genome Editing Toolbox: YTDE & YolBE
- AI-Powered Discovery Platform using Metagenomics Data
- Proprietary Lipid Library of novel ionizable cationic lipids
- High-throughput screening and optimization for LNP selection
- GMP production platform for large-scale LNP-mRNA and in vivo gene editing drug manufacture
- Demonstrated 5x better delivery rate to liver/non-liver organs (spleen, bone marrow) compared to international counterparts
- Strong IP protection with no infringement issues